Del Mar, Guangxi Wuzhou join forces to develop VAL-083
VAL-083 has received the Chinese State Food and Drug Administration (SFDA) approval as cancer chemotherapy to treat Chronic Myelogenous Leukemia (CML) and lung cancer. The companies are also
Bristol Myers Squibb (BMS) is set to merge its separate research and development (R&D) departments into a single entity, effective from 1 January 2027.
The partnership is expected to develop reusable transport packaging solutions that enable pharmaceutical shippers and others to improve cold chain operations management. The technology will provide on-demand data